Meeting
2023 ASCO Genitourinary Cancers Symposium
Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-in-human study.
Authors
Antoni Vilaseca
Hospital Clínic de Barcelona, Barcelona, Spain
Antoni Vilaseca , Félix Guerrero , Daniel Zainfeld , Neal D. Shore , Oscar Rodriguez Faba , Richard P. Meijer , Alfred Alfred Witjes , Autumn Jackson McRee , Anna Kalota , Nicole L. Stone , Josh David Lauring , Wei Zhu , Neil Beeharry , Lang A O'Dondi , Gautam Jayram
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05316155
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS583)
DOI
10.1200/JCO.2023.41.6_suppl.TPS583
Abstract #
TPS583
Poster Bd #
P6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I dose-escalation clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in patients with recurrent or refractory non-myoinvasive bladder cancer.
First Author: Hizra Farrukh
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-676 cohort A: Bacillus Calmette-Guérin (BCG) with or without pembrolizumab for high-risk (HR) non–muscle-invasive bladder cancer (NMIBC) that persists/recurs after BCG induction.
First Author: Neal D. Shore
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab with favezelimab or vibostolimab for patients with bacillus Calmette-Guérin (BCG)–unresponsive high-risk (HR) non–muscle-invasive bladder cancer (NMIBC): Phase 2 KEYNOTE-057 cohort C.
First Author: Girish S. Kulkarni
Poster
2023 ASCO Annual Meeting
Phase 2 trial of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) for the treatment of non-muscle invasive BCG unresponsive urothelial carcinoma of the bladder.
First Author: Guarionex Joel DeCastro